Zacks: Analysts Expect Evoke Pharma Inc (NASDAQ:EVOK) to Announce -$0.12 Earnings Per Share

Wall Street analysts expect Evoke Pharma Inc (NASDAQ:EVOK) to announce earnings of ($0.12) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Evoke Pharma’s earnings. Evoke Pharma reported earnings per share of ($0.14) during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.3%. The company is expected to issue its next earnings results on Thursday, August 15th.

According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.35) per share for the current financial year. For the next financial year, analysts expect that the company will post earnings of ($0.19) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03.

A number of equities analysts recently commented on EVOK shares. HC Wainwright reiterated a “hold” rating on shares of Evoke Pharma in a research note on Friday, August 9th. ValuEngine upgraded Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Tuesday.

Large investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in Evoke Pharma in the second quarter valued at approximately $37,000. Marshall Wace LLP acquired a new stake in Evoke Pharma in the 1st quarter worth about $139,000. Virtu Financial LLC acquired a new stake in Evoke Pharma in the 1st quarter worth about $118,000. Finally, BlackRock Inc. raised its stake in Evoke Pharma by 5.5% in the 4th quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock worth $207,000 after purchasing an additional 4,392 shares in the last quarter. Institutional investors and hedge funds own 7.40% of the company’s stock.

NASDAQ:EVOK traded up $0.02 during mid-day trading on Thursday, reaching $0.86. The stock had a trading volume of 135,076 shares, compared to its average volume of 712,145. The stock has a market cap of $19.31 million, a P/E ratio of -1.87 and a beta of 1.62. Evoke Pharma has a 1-year low of $0.50 and a 1-year high of $3.40. The business has a 50 day simple moving average of $0.89.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Recommended Story: What is meant by a buy rating?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.